<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>PILMAN &#187; prescription</title>
	<atom:link href="http://www.tapanray.in/tag/prescription/feed/" rel="self" type="application/rss+xml" />
	<link>http://www.tapanray.in</link>
	<description>A Tapan Ray Website</description>
	<lastBuildDate>Sun, 22 Mar 2026 10:59:18 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.4.2</generator>
		<item>
		<title>Drug Prescription In Generic Names Only, No Branded Generics</title>
		<link>http://www.tapanray.in/drug-prescription-in-generic-names-only-no-branded-generics/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=drug-prescription-in-generic-names-only-no-branded-generics</link>
		<comments>http://www.tapanray.in/drug-prescription-in-generic-names-only-no-branded-generics/#comments</comments>
		<pubDate>Sun, 20 Aug 2023 07:24:49 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Access]]></category>
		<category><![CDATA[accountability.]]></category>
		<category><![CDATA[awareness]]></category>
		<category><![CDATA[branded generics]]></category>
		<category><![CDATA[companies]]></category>
		<category><![CDATA[competition]]></category>
		<category><![CDATA[concern]]></category>
		<category><![CDATA[Cost]]></category>
		<category><![CDATA[Counterfeit]]></category>
		<category><![CDATA[demand]]></category>
		<category><![CDATA[doctors]]></category>
		<category><![CDATA[Draft]]></category>
		<category><![CDATA[Drug]]></category>
		<category><![CDATA[generic]]></category>
		<category><![CDATA[IMA]]></category>
		<category><![CDATA[increased]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[industry]]></category>
		<category><![CDATA[influence]]></category>
		<category><![CDATA[lack]]></category>
		<category><![CDATA[medicine]]></category>
		<category><![CDATA[names]]></category>
		<category><![CDATA[notification]]></category>
		<category><![CDATA[Patient]]></category>
		<category><![CDATA[pharmaceutical]]></category>
		<category><![CDATA[prescription]]></category>
		<category><![CDATA[Quality]]></category>
		<category><![CDATA[rationale]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Regulation]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[transparency]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=10812</guid>
		<description><![CDATA[The World Bank Report released on April 07, 2023 highlights that patients&#8217; Out-of-Pocket (OoP) expenses as a percentage of their total healthcare expenditure in India still accounted for as high as 50.59%. This means that patients in India generally pay for the &#8230; <a href="http://www.tapanray.in/drug-prescription-in-generic-names-only-no-branded-generics/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/drug-prescription-in-generic-names-only-no-branded-generics/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Growing Intricacies of Today’s Field Staff Role And The Path Ahead</title>
		<link>http://www.tapanray.in/growing-intricacies-of-todays-field-staff-role-and-the-path-ahead/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=growing-intricacies-of-todays-field-staff-role-and-the-path-ahead</link>
		<comments>http://www.tapanray.in/growing-intricacies-of-todays-field-staff-role-and-the-path-ahead/#comments</comments>
		<pubDate>Mon, 30 Jan 2023 00:00:23 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[customer]]></category>
		<category><![CDATA[demand]]></category>
		<category><![CDATA[digital]]></category>
		<category><![CDATA[Drug]]></category>
		<category><![CDATA[e-detailing]]></category>
		<category><![CDATA[e-marketing]]></category>
		<category><![CDATA[engagement]]></category>
		<category><![CDATA[field. staff]]></category>
		<category><![CDATA[Generation]]></category>
		<category><![CDATA[hybrid]]></category>
		<category><![CDATA[hybridization]]></category>
		<category><![CDATA[in]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[intricacies]]></category>
		<category><![CDATA[marketing]]></category>
		<category><![CDATA[model]]></category>
		<category><![CDATA[omnichannel]]></category>
		<category><![CDATA[outsourcing]]></category>
		<category><![CDATA[prescription]]></category>
		<category><![CDATA[pull]]></category>
		<category><![CDATA[Push]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[role]]></category>
		<category><![CDATA[sales]]></category>
		<category><![CDATA[strategies]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[traditional]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=10742</guid>
		<description><![CDATA[With a varying degree, and in various forms, a hybrid working model is now gaining greater acceptance of several top pharma companies, across the world, just as in many other industries. This trend gets echoed in an article of December 07, 2022, &#8230; <a href="http://www.tapanray.in/growing-intricacies-of-todays-field-staff-role-and-the-path-ahead/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/growing-intricacies-of-todays-field-staff-role-and-the-path-ahead/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Restart Pharma Demand Generation Activities With Actionable Insight</title>
		<link>http://www.tapanray.in/restart-pharma-demand-generation-activities-with-actionable-insight/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=restart-pharma-demand-generation-activities-with-actionable-insight</link>
		<comments>http://www.tapanray.in/restart-pharma-demand-generation-activities-with-actionable-insight/#comments</comments>
		<pubDate>Mon, 01 Jun 2020 00:00:34 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Actionable]]></category>
		<category><![CDATA[activity]]></category>
		<category><![CDATA[bedrock]]></category>
		<category><![CDATA[changes]]></category>
		<category><![CDATA[Coronavirus]]></category>
		<category><![CDATA[COVID-19]]></category>
		<category><![CDATA[data]]></category>
		<category><![CDATA[demand]]></category>
		<category><![CDATA[distancing]]></category>
		<category><![CDATA[Generation]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[Information]]></category>
		<category><![CDATA[innovative]]></category>
		<category><![CDATA[Insishr]]></category>
		<category><![CDATA[new normal]]></category>
		<category><![CDATA[pathway]]></category>
		<category><![CDATA[prescription]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[restart]]></category>
		<category><![CDATA[Social]]></category>
		<category><![CDATA[Social-distancing]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=10107</guid>
		<description><![CDATA[As the ‘Lockdown. 04’ in India passes by, a time comes to press the restart button of all business activities in the country, in a calibrated manner, though, keeping in mind, the Covid-19 cases is yet to find its peak &#8230; <a href="http://www.tapanray.in/restart-pharma-demand-generation-activities-with-actionable-insight/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/restart-pharma-demand-generation-activities-with-actionable-insight/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Come Covid-19 Drug And Vaccine, Pharma Will Get Back To The Traditional Mode</title>
		<link>http://www.tapanray.in/come-covid-19-drug-and-vaccine-pharma-will-get-back-to-the-traditional-mode/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=come-covid-19-drug-and-vaccine-pharma-will-get-back-to-the-traditional-mode</link>
		<comments>http://www.tapanray.in/come-covid-19-drug-and-vaccine-pharma-will-get-back-to-the-traditional-mode/#comments</comments>
		<pubDate>Mon, 18 May 2020 00:00:53 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[abbott]]></category>
		<category><![CDATA[Access]]></category>
		<category><![CDATA[Affordability]]></category>
		<category><![CDATA[Coronavirus]]></category>
		<category><![CDATA[COVID-19]]></category>
		<category><![CDATA[demand]]></category>
		<category><![CDATA[distancing]]></category>
		<category><![CDATA[Drug]]></category>
		<category><![CDATA[effective]]></category>
		<category><![CDATA[epidemic]]></category>
		<category><![CDATA[Generation]]></category>
		<category><![CDATA[HiNI]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[mode]]></category>
		<category><![CDATA[pandemic]]></category>
		<category><![CDATA[prescription]]></category>
		<category><![CDATA[proven]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[safe]]></category>
		<category><![CDATA[scientifically]]></category>
		<category><![CDATA[Social]]></category>
		<category><![CDATA[speedy]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[testing]]></category>
		<category><![CDATA[traditional]]></category>
		<category><![CDATA[Vaccine]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=10084</guid>
		<description><![CDATA[‘Corona will remain a part of our lives for a long time. But at the same time, we cannot allow this to happen that our lives will be confined only around the corona. We would wear masks, follow two yards &#8230; <a href="http://www.tapanray.in/come-covid-19-drug-and-vaccine-pharma-will-get-back-to-the-traditional-mode/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/come-covid-19-drug-and-vaccine-pharma-will-get-back-to-the-traditional-mode/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>OTC Drugs in India: ‘Where Art Thou?’</title>
		<link>http://www.tapanray.in/otc-drugs-in-india-where-art-thou/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=otc-drugs-in-india-where-art-thou</link>
		<comments>http://www.tapanray.in/otc-drugs-in-india-where-art-thou/#comments</comments>
		<pubDate>Mon, 02 Sep 2019 00:00:26 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Act]]></category>
		<category><![CDATA[advertisement]]></category>
		<category><![CDATA[amendment]]></category>
		<category><![CDATA[classification]]></category>
		<category><![CDATA[D&C]]></category>
		<category><![CDATA[dangerous]]></category>
		<category><![CDATA[drugs]]></category>
		<category><![CDATA[ethical]]></category>
		<category><![CDATA[illegal]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[juggernaut]]></category>
		<category><![CDATA[Medicines]]></category>
		<category><![CDATA[non-prescription]]></category>
		<category><![CDATA[OTC]]></category>
		<category><![CDATA[Over The Counter]]></category>
		<category><![CDATA[prescription]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[responsible]]></category>
		<category><![CDATA[rule]]></category>
		<category><![CDATA[schedule K]]></category>
		<category><![CDATA[self-medication]]></category>
		<category><![CDATA[standards]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[US_FDA]]></category>
		<category><![CDATA[Where Art Thou]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=9692</guid>
		<description><![CDATA[It is now a widely accepted fact that responsible self-medication plays an important role in health care, facilitating greater access to medicines and reducing overall health care cost. With continued improvement in people&#8217;s education, general knowledge and socioeconomic conditions, self-medication has &#8230; <a href="http://www.tapanray.in/otc-drugs-in-india-where-art-thou/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/otc-drugs-in-india-where-art-thou/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Are Cancer Patients Victims of Pharma’s Payment to Doctors &#8211; For Prescriptions?</title>
		<link>http://www.tapanray.in/are-cancer-patients-victims-of-pharmas-payment-to-doctors-for-prescriptions/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=are-cancer-patients-victims-of-pharmas-payment-to-doctors-for-prescriptions</link>
		<comments>http://www.tapanray.in/are-cancer-patients-victims-of-pharmas-payment-to-doctors-for-prescriptions/#comments</comments>
		<pubDate>Mon, 04 Mar 2019 00:00:59 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[cancer]]></category>
		<category><![CDATA[Catering]]></category>
		<category><![CDATA[Cost]]></category>
		<category><![CDATA[doctors]]></category>
		<category><![CDATA[Drug]]></category>
		<category><![CDATA[Evaluation]]></category>
		<category><![CDATA[high]]></category>
		<category><![CDATA[immunotherapy]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[industry]]></category>
		<category><![CDATA[innovation]]></category>
		<category><![CDATA[marketing]]></category>
		<category><![CDATA[oncology]]></category>
		<category><![CDATA[Patients]]></category>
		<category><![CDATA[pay]]></category>
		<category><![CDATA[practices]]></category>
		<category><![CDATA[Prescribing]]></category>
		<category><![CDATA[prescription]]></category>
		<category><![CDATA[prices]]></category>
		<category><![CDATA[relatioship]]></category>
		<category><![CDATA[Sloan]]></category>
		<category><![CDATA[UCPMP]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=9432</guid>
		<description><![CDATA[In pharma industry, people of all socioeconomic backgrounds have no other choice but to visit doctors, to seek their expert advice for medical treatment. Patients expect them to prescribe the right and most affordable medicines for desired relief. Ironically, it &#8230; <a href="http://www.tapanray.in/are-cancer-patients-victims-of-pharmas-payment-to-doctors-for-prescriptions/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/are-cancer-patients-victims-of-pharmas-payment-to-doctors-for-prescriptions/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>An Interesting demand: No Price Control For OTC Drugs</title>
		<link>http://www.tapanray.in/an-interesting-demand-no-price-control-for-otc-drugs/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=an-interesting-demand-no-price-control-for-otc-drugs</link>
		<comments>http://www.tapanray.in/an-interesting-demand-no-price-control-for-otc-drugs/#comments</comments>
		<pubDate>Mon, 19 Nov 2018 00:00:50 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Access]]></category>
		<category><![CDATA[Affordability]]></category>
		<category><![CDATA[Association]]></category>
		<category><![CDATA[benefits]]></category>
		<category><![CDATA[control]]></category>
		<category><![CDATA[decontrol]]></category>
		<category><![CDATA[Drug]]></category>
		<category><![CDATA[Essential]]></category>
		<category><![CDATA[Expenses]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[medicine]]></category>
		<category><![CDATA[oop]]></category>
		<category><![CDATA[OTC]]></category>
		<category><![CDATA[out of pocket]]></category>
		<category><![CDATA[outside]]></category>
		<category><![CDATA[Over The Counter]]></category>
		<category><![CDATA[Patients]]></category>
		<category><![CDATA[Policy]]></category>
		<category><![CDATA[prescription]]></category>
		<category><![CDATA[price]]></category>
		<category><![CDATA[Promotion]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Regulatory]]></category>
		<category><![CDATA[switch]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[Trade]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=9286</guid>
		<description><![CDATA[Since over a decade, some pharma trade organizations operating in India, have been advocating for a separate regulatory policy for ‘Over The Counter (OTC)’ drugs, which can be legally sold without any medical prescriptions. Such a new policy initiative, if taken by &#8230; <a href="http://www.tapanray.in/an-interesting-demand-no-price-control-for-otc-drugs/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/an-interesting-demand-no-price-control-for-otc-drugs/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Prescription Digital Therapy Now A Reality</title>
		<link>http://www.tapanray.in/prescription-digital-therapy-now-a-reality/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=prescription-digital-therapy-now-a-reality</link>
		<comments>http://www.tapanray.in/prescription-digital-therapy-now-a-reality/#comments</comments>
		<pubDate>Mon, 07 May 2018 00:00:46 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[2]]></category>
		<category><![CDATA[3]]></category>
		<category><![CDATA[app]]></category>
		<category><![CDATA[Apple]]></category>
		<category><![CDATA[approval]]></category>
		<category><![CDATA[behavior]]></category>
		<category><![CDATA[chronic]]></category>
		<category><![CDATA[cognition]]></category>
		<category><![CDATA[diabetic]]></category>
		<category><![CDATA[digiceuticals]]></category>
		<category><![CDATA[digital]]></category>
		<category><![CDATA[disease]]></category>
		<category><![CDATA[disorder]]></category>
		<category><![CDATA[Epilepsy]]></category>
		<category><![CDATA[fitness]]></category>
		<category><![CDATA[Health]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[MDD]]></category>
		<category><![CDATA[mood]]></category>
		<category><![CDATA[Novartis]]></category>
		<category><![CDATA[Parkinson's]]></category>
		<category><![CDATA[Pear]]></category>
		<category><![CDATA[Pears]]></category>
		<category><![CDATA[potential]]></category>
		<category><![CDATA[prescription]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[reality]]></category>
		<category><![CDATA[Regulatory]]></category>
		<category><![CDATA[reSet]]></category>
		<category><![CDATA[Sandoz]]></category>
		<category><![CDATA[scope]]></category>
		<category><![CDATA[seizures]]></category>
		<category><![CDATA[Substance]]></category>
		<category><![CDATA[Takeda]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[Therapeutics]]></category>
		<category><![CDATA[therapy]]></category>
		<category><![CDATA[use]]></category>
		<category><![CDATA[version]]></category>
		<category><![CDATA[Watch]]></category>
		<category><![CDATA[wealthy]]></category>
		<category><![CDATA[wearable]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=8981</guid>
		<description><![CDATA[The pursuit of offering ‘prescription digital therapeutics’ or ‘digiceuticals’ by Big Pharma, to ensure better clinical outcomes for patients, has apparently come to fruition now. On April 18, 2018, by a media release, Novartis announced that the Sandoz Division of the Company &#8230; <a href="http://www.tapanray.in/prescription-digital-therapy-now-a-reality/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/prescription-digital-therapy-now-a-reality/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>How Relevant Is A Pharma Brand Name To Patients?</title>
		<link>http://www.tapanray.in/how-relevant-is-a-pharma-brand-name-to-patients/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=how-relevant-is-a-pharma-brand-name-to-patients</link>
		<comments>http://www.tapanray.in/how-relevant-is-a-pharma-brand-name-to-patients/#comments</comments>
		<pubDate>Mon, 26 Feb 2018 00:00:45 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[branding]]></category>
		<category><![CDATA[Connect]]></category>
		<category><![CDATA[consumer]]></category>
		<category><![CDATA[counter]]></category>
		<category><![CDATA[direct]]></category>
		<category><![CDATA[drugs]]></category>
		<category><![CDATA[DTC]]></category>
		<category><![CDATA[emotional]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[Medicines]]></category>
		<category><![CDATA[OTC]]></category>
		<category><![CDATA[outcomes]]></category>
		<category><![CDATA[over]]></category>
		<category><![CDATA[Patients]]></category>
		<category><![CDATA[prescription]]></category>
		<category><![CDATA[Quality]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Relevance]]></category>
		<category><![CDATA[relevant]]></category>
		<category><![CDATA[Safety]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[treatment]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=8832</guid>
		<description><![CDATA[Are brand names necessary for medicines? Well – its’s a contentious issue, at least, as on date. It becomes the subject of a raging debate when the same question is slightly modified to: &#8211; Are brand names necessary for prescription &#8230; <a href="http://www.tapanray.in/how-relevant-is-a-pharma-brand-name-to-patients/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/how-relevant-is-a-pharma-brand-name-to-patients/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Should ‘Pharma Marketing’ Be In The Line of Fire?</title>
		<link>http://www.tapanray.in/should-pharma-marketing-be-in-the-line-of-fire/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=should-pharma-marketing-be-in-the-line-of-fire</link>
		<comments>http://www.tapanray.in/should-pharma-marketing-be-in-the-line-of-fire/#comments</comments>
		<pubDate>Sun, 26 Nov 2017 23:31:21 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA['condo']]></category>
		<category><![CDATA[ails]]></category>
		<category><![CDATA[Allegation]]></category>
		<category><![CDATA[Business]]></category>
		<category><![CDATA[Cost]]></category>
		<category><![CDATA[data]]></category>
		<category><![CDATA[decision]]></category>
		<category><![CDATA[drugs]]></category>
		<category><![CDATA[fire]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[intrinsic]]></category>
		<category><![CDATA[line]]></category>
		<category><![CDATA[Malpractices]]></category>
		<category><![CDATA[marketing]]></category>
		<category><![CDATA[medication]]></category>
		<category><![CDATA[OTC]]></category>
		<category><![CDATA[prescription]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[serious]]></category>
		<category><![CDATA[support]]></category>
		<category><![CDATA[system]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[UCPMP]]></category>
		<category><![CDATA[UHC]]></category>
		<category><![CDATA[value]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=8570</guid>
		<description><![CDATA[Close to half a century ago, Peter Drucker &#8211; the Management Guru wrote: As the purpose of business is to create customers, any business enterprise has two basic functions: marketing and innovation. Drucker’s concept is so fundamental in nature that it will possibly never change, ever. That innovation &#8230; <a href="http://www.tapanray.in/should-pharma-marketing-be-in-the-line-of-fire/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/should-pharma-marketing-be-in-the-line-of-fire/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>
